Janssen R&D (Ireland) has described respiratory syncytial virus (RSV) inhibiting spiro-bearing derivatives reported to be potentially useful for the treatment of RSV infections.
Akthelia Pharmaceuticals ehf and the University of Iceland have announced the successful joint award of a €6 million (US$6.6 million) EU Horizon Grant to fund the IN-ARMOR project that seeks to address antimicrobial resistance (AMR).
Clevudine derivatives and its phosphoramidates have been detailed in an Emory University patent as potentially useful for the treatment of hepatitis B virus (HBV) infection.
Research at Pardes Biosciences Inc. has led to the identification of cysteine protease inhibitors, particularly 3C-like proteinase (3CLpro, Mpro, nsp5; SARS-CoV-2) and Mpro (HCoV-229E virus) inhibitors, reported to be useful for the treatment of viral infections.
Veru Inc. announced results from an in vitro study evaluating the effects of sabizabulin against a prototypical poxvirus, vaccinia virus, which demonstrated that sabizabulin prevented both the release of poxvirus from infected cells and the spread of poxvirus to healthy cells.
Researchers from Shandong Academy of Agricultural Science reported the discovery of novel pleuromutilin derivatives as potential antibiotic agents. Synthesis and optimization of a series of pyridinium cation-substituted pleuromutilin analogues led to the identification of compound [I] as the lead candidate with potent antibacterial activity.
A recent F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. patent describes compounds reported to be useful for the treatment of Escherichia coli infection.
RSS
